TY  - JOUR
A1  - Keber, Timo
A1  - Bönisch, Harald
A1  - Hartick, Carl
A1  - Hauck, Marius
A1  - Lefrancois, Fides
A1  - Obersteiner, Florian
A1  - Ringsdorf, Akima
A1  - Schohl, Nils
A1  - Schuck, Tanja J.
A1  - Hossaini, Ryan
A1  - Graf, Phoebe
A1  - Jöckel, Patrick
A1  - Engel, Andreas
T1  - Bromine from short-lived source gases in the extratropical northern hemispheric upper troposphere and lower stratosphere (UTLS)
T2  - Atmospheric chemistry and physics
N2  - Background: Point of care devices for performing targeted coagulation substitution in bleeding patients have become increasingly important in recent years. New on the market is the Quantra® from HemoSonics (LC, Charlottesville, VA, US). It uses sonorheometry, a sonic estimation of elasticity via resonance (SEER), a novel ultrasound-based technology that measures viscoelastic properties of whole blood. Several studies have already shown the comparability with devices already established on the market such as the ROTEM® (TEM International GmbH, Munich, Germany). 
Objective: In contrast to existing studies, the planned study will be the first prospective interventional study using the new Quantra® system in a cardiac surgical patient cohort. The aim is to investigate the non-inferiority between an already existing coagulation algorithm, based on ROTEM®/Multiplate®, and a new algorithm based on the Quantra®, for the treatment of coagulopathic cardiac surgical patients. 
Methods: The study is divided into two phases. In an initial observation phase, whole blood samples of 20 patients will be analyzed using both ROTEM®/Multiplate® and Quantra® obtained at three defined points of time (prior to surgery, after completion of cardiopulmonary bypass, on arrival in the intensive care unit). The obtained threshold values will be used to create an algorithm for hemotherapy. In a second intervention phase, the new algorithm will be tested against an algorithm used routineously for years at our department for non-inferiority. 
Results: The main objective of the examination is the cumulative loss of blood within 24 hours after surgery. Statistical calculations based on literature and in-house data suggest that the new algorithm is not inferior if the difference in cumulative blood loss is < 150ml/24 h. 
Conclusions: Because of the comparability of the Quantra® sonorheometry system with ROTEM® rotational thromboelastometric measurement methods, the existing hemotherapy treatment algorithm can be adapted to the Quantra device with a proof of non-inferiority. Clinical Trial: International Registered Report Identifier (IRRID): clinicaltrials.gov: NCT03902275
Y1  - 2020
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/55261
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-552619
SN  - 1680-7324
SN  - 1680-7316
N1  - This work is distributed under the Creative Commons Attribution 4.0 License.
N1  - doi:10.5194/acp-20-4105-2020-supplement Supplement-Datei
VL  - 20
SP  - 4105
EP  - 4132
PB  - Copernicus
CY  - Göttingen
ER  -